fda compounding semaglutide crackdown news today The FDA's GLP-1 Continues: What to Know FDA Intensifies Crackdown on GLP-1

Figure 7: Photograph of Leonard Thompson in 1930 together with (A) his medical record and (B) chart of his blood sugar levels from December 1921 to January 1922 (credit:Thomas Fisher Rare Book Library, University of Toronto)

Minimum 0.81g per pound of bodyweight

Ituarte BE, et al

- **60mg** -- Best value for higher-dose users (8-12mg)

Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist not yet licensed in the UK or approved by the MHRA or EMA

Treatment discontinuation due to gastrointestinal events occurred in a minority of patients, and overall, serious adverse events were similar to those with the placebo